Physician profile
Melissa Piech
NPI 1326240730
$284.01
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $102 · 2022: $21.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.25 | 2019-2020 | |
| Radius Health, INC. | $38.86 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $27.57 | 2020 | |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Abbvie INC. | $24.99 | 2019 | |
| Abbott Laboratories | $21.23 | 2022 | |
| Aytu Biopharma, INC. | $20.68 | 2019 | |
| Tandem Diabetes Care, INC. | $19.79 | 2020 | |
| Lilly USA, LLC | $18.06 | 2019 | |
| Ibsa Pharma INC. | $15.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.45 | 2019 | |
| Dexcom, INC. | $12.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Piech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.